Trial Profile
A Retrospective Analysis of Electronic Health Records examining the effectiveness of two parenteral iron formulations (ferric carboxymaltose [FCM] and ferumoxytol [FM]) in the real world setting.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Dec 2017
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary) ; Ferumoxytol (Primary)
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- 21 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology